Dusseldorf - Delayed Quote EUR

Unity Biotechnology Inc (9U90.DU)

0.7090
-0.0810
(-10.25%)
As of 12:32:25 PM GMT+2. Market Open.
All All Favorites Text Statistics Technicals Fibonacci Markings Lines
Loading Chart for 9U90.DU

Recent News: 9U90.DU

View More
Bluebird pleads for deal support; Unity, Mersana lay off staff

Bluebird pleads for deal support; Unity, Mersana lay off staff
BioPharma Dive 8 days ago
UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of UBX1325 in Diabetic Macular Edema and Provides Corporate Updates

UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of UBX1325 in Diabetic Macular Edema and Provides Corporate Updates
GlobeNewswire 9 days ago
UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting

UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting
GlobeNewswire 13 days ago
UNITY Biotechnology Announces Publication in NEJM Evidence Highlighting the Potential of Senolytic Therapeutics to Provide Long-Term Improvements in Vision in DME

UNITY Biotechnology Announces Publication in NEJM Evidence Highlighting the Potential of Senolytic Therapeutics to Provide Long-Term Improvements in Vision in DME
GlobeNewswire 21 days ago
UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates

UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates
GlobeNewswire 21 days ago
UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study

UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study
Zacks last month
Unity reports topline outcomes from trial of diabetic macular oedema therapy

Unity reports topline outcomes from trial of diabetic macular oedema therapy
Clinical Trials Arena last month
UNITY Biotechnology Shares Drop 33% After Phase 2b Trial Data on UBX1325 in Diabetic Macular Edema

UNITY Biotechnology Shares Drop 33% After Phase 2b Trial Data on UBX1325 in Diabetic Macular Edema
GuruFocus.com last month
UNITY Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in Diabetic Macular Edema

UNITY Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in Diabetic Macular Edema
GlobeNewswire last month
UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE Study of UBX1325 in Patients with Diabetic Macular Edema (DME) on March 24, 2025

UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE Study of UBX1325 in Patients with Diabetic Macular Edema (DME) on March 24, 2025
GlobeNewswire last month
UNITY Biotechnology Appoints Industry Leader and Ophthalmology Expert Yehia Hashad, M.D., to the Board of Directors

UNITY Biotechnology Appoints Industry Leader and Ophthalmology Expert Yehia Hashad, M.D., to the Board of Directors
GlobeNewswire 2 months ago
View More

Related Tickers

CPMV Mosaic ImmunoEngineering, Inc.
0.5400
+5.53%
 
BNTX BioNTech SE
94.50
-2.85%
 
DNA Ginkgo Bioworks Holdings, Inc.
8.12
-2.29%
 
MRNA Moderna, Inc.
25.49
-0.82%